WHAT THIS PAPER ADDS Abdominal aortic aneurysms generally enlarge and rupture unless resected or repaired. To date, pharmacological strategy has proven ineffective in preventing disease progression. In this study, rapamycin proved remarkably effective in preventing progression of established experimental aneurysms. Despite beginning therapy after aneurysm initiation, rapamycin preserved aortic architecture, and attenuated aortic mural angiogenesis and macrophage accumulation. This study adds to the growing body of evidence supporting the use of rapamycin for medical abdominal aortic aneurysm disease management.
INTRODUCTION
Abdominal aortic aneurysm (AAA) is a lethal, age-and gender-related chronic inflammatory disease. Approximately one million Americans aged 50e84 years 1 are at risk for premature, AAA-related death. Key pathological features present in AAA disease include mural leukocyte infiltration, neoangiogenesis, smooth muscle cell (SMC) depletion, extracellular matrix degradation, and progressive intraluminal laminar thrombus accumulation. 2 Although multiple pharmacological inhibition strategies have succeeded in experimental aneurysm models, 3e10 none have been successfully translated to clinical practice. Therefore, surgical repair, limited to patients suffering from advanced disease, remains the only available option. Rapamycin is approved by the US Food and Drug Administration for preventing rejection of transplant allografts, as well as coronary artery restenosis following transluminal angioplasty and stenting. 14, 15 Mechanistically, rapamycin disrupts cellular signaling through mechanistic/ mammalian target of rapamycin (mTOR), a serine/threonine kinase modulating numerous biological processes, including cell growth, metabolism, aging, angiogenesis, and inflammation. 16 In experimental atherosclerosis, rapamycin treatment increases plaque stability and limits disease progression.
17e19 Rapamycin is effective in limiting experimental aneurysm progression when administered prior to AAA initiation.which point the aneurysmal degeneration has been initiated. Rapamycin is remarkably effective in limiting progression in this construct, further highlighting the translational potential of this therapeutic strategy.
MATERIALS AND METHODS

Animals
Male C57BL/6J mice aged 10e12 weeks were used for all experiments. All animal protocols were in compliance with the Laboratory Animal Care Guidelines of Stanford University, and reviewed and approved by the Stanford University Administrative Panel on Laboratory Animal Care.
Aneurysm creation and follow-up
AAAs were created via intra-aortic PPE infusion as previously described. 8, 22 Briefly, under inhaled anesthesia and under operative magnification, 30 mL of type 1 PPE (1.5 U/ mL in saline, Catalog # 098K7008; Sigma-Aldrich, St. Louis, MO, USA) was infused for 5 minutes into an isolated segment of infrarenal aorta. At days 3, 7, and 14 after the infusion procedure, the aortic diameter was measured serially using the Vevo 770 ultrasound system (40 MHz RMV-704 Scanhead with a resolution of 30 mm; VisualSonics, Toronto, ON, Canada). 8, 22 Two investigators performed all measurements independently, without knowledge of study group assignment.
Rapamycin treatment
Rapamycin was purchased from the LC Laboratories (Woburn, MA, USA) and prepared in 0.2% carboxy-methylcellulose immediately prior to use. Mice were treated daily with 5 mg/kg rapamycin or an equal volume of vehicle alone via oral gavage, depending on study group assignment, beginning 4 days after PPE infusion and continuing for 10 days. This dose was chosen based on a literature review of published work in atherosclerosis models. 
Histological analyses
Aortae were harvested 14 days after PPE infusion, embedded in optimal cutting compound media, sectioned (6 mm), and fixed with cold acetone. Elastin integrity was evaluated using Verhoeff's Van Gieson (EVG) stain. SMCs, macrophages, and angiogenesis were stained with antibodies against SMC a actin, CD68, and CD31, respectively, using a standard three-step biotinestreptavidineperoxidase immunostain. 8, 22 Based on EVG and SMC a actin staining, destruction of medial elastin and SMCs were graded as I (mild) to IV (severe) if present: 8, 22 (I): elastin break/degradation or SMC loss limited to one outer medial elastin layer; (II): elastin degradation or SMC loss involving more than two medial elastin layers, or entire medial elastin layers, but limited to less than one-quarter of the aortic circumference; (III): elastin degradation or SMC loss involving entire medial elastin layers, but limited to less than half the aortic circumference; and (IV): elastin degradation or SMC loss involving entire medial elastin layers and expanded to more than three-quarters of aortic circumference. Mural macrophages and angiogenesis were quantified as CD68 þ cells and CD31 þ blood vessels, respectively, per aortic cross section (ACS).
Statistical analysis
All data are presented as mean and standard deviation (SD), and were analyzed using GraphPad Prism (version 5a; GraphPad Software, La Jolla, CA, USA). Two-way ANOVA (using the Bonferroni correction for multiple comparisons) or the non-parametric ManneWhitney test was used to identify differences between groups. Significance was assumed at p < .05.
RESULTS
Effects of rapamycin treatment on further progression of established aneurysms
In our prior experience with this model, most mice develop characteristic histological features and > 50.0% infrarenal diameter enlargement consistent with AAA formation within 3e4 days of PPE infusion. 8 To evaluate the ability of rapamycin to limit progression of established AAAs, mice were treated with 5 mg/kg/d rapamycin via oral gavage, beginning 4 days after the PPE infusion and continuing for 10 days in total. Prior to drug or vehicle treatment (3 days after PPE infusion), five and six mice in the vehicle and rapamycin groups, respectively, developed AAAs as defined by a > 50.0% increase in aortic diameters over the baseline levels. As demonstrated in Fig. 1 , rapamycin treatment was associated with a small, but significant, loss of weight during the course of the experiment (103.8 AE 4.9% and 97.2 AE 3.6% of baseline levels in vehicle and rapamycin groups, respectively; p < .05). Fig. 2 demonstrates the timedependent progression of aortic diameter, as determined by ultrasound imaging. In vehicle-treated mice, aortic diameters increased by an average of 0.13 and 0.36 mm between days 3 and 10, respectively. In contrast, treatment with rapamycin resulted in remarkable attenuation of Figure 1 . Effect of rapamycin treatment on body weight. Data on body weight are presented as the percentage of baseline levels (prior to vehicle or rapamycin treatment). Two-way analysis of variance with the Bonerroni correction, p < .01 between two groups; n ¼ 7e8 mice/group. further enlargement, with growth averaging 0.07 and 0.17 mm for days 3 and 10, respectively, corresponding to a 38.0e53.0% reduction (p < .05 compared with vehicle group). In this context, therefore, rapamycin treatment appears effective in limiting further progression of established experimental AAA.
Effects of rapamycin treatment on medial elastin and SMCs
Medial elastin destruction and SMC depletion are hallmarks of AAA histopathology.To examine the influence of rapamycin therapy on aortic structural integrity, EVG and SMC a-actin staining was performed on aortic samples (Fig. 3) . As indicated by semi-quantitative analysis, rapamycin treatment resulted in significant aortic SMC retention compared with vehicle treatment alone (p < .05). Further confirmation was obtained by counting SMC a-actin-positive cells in the aortic media (56.3 AE 8.4 and 32.7 AE 16.2 cells/ACS in rapamycin and vehicle-treated groups, respectively; p < 0.05). Although some aortic elastin preservation was apparent in rapamycintreated mice, this difference was not significant. These findings suggest a potential mechanism for rapamycin-induced AAA suppression, specifically augmentation of aortic SMC retention/preservation.
Effects of rapamycin treatment on mural macrophage infiltration and angiogenesis
Macrophage accumulation and mural neoangiogenesis also represent characteristic histopathologic features of abdominal aortic degeneration. Mural macrophage density and angiogenesis was examined in frozen aortic sections using CD68 and CD31 monoclonal antibody immunostaining, respectively. Numerous mural macrophages were present in the aneurysmal aortae of vehicle-treated mice (352 AE 125 cells/ACS) (Fig. 4A, B) . In rapamycin-treated mice, macrophage density was reduced by 75.0% (90 AE 57 cells/ACS, p < .01). Similarly, adventitial CD31 þ neovessel density was significantly lower (3 AE 3 blood vessels/ACS) than in vehicle-treated mice (19 AE 12 blood vessels/ACS), representing an 85.0% reduction (Fig. 4A, C) (p < .01). These results suggest, in addition to effects on SMC preservation, that rapamycin therapy may limit aneurysmal degeneration via suppression of mural macrophage accumulation and adventitial neoangiogenesis.
DISCUSSION
In this study, we found rapamycin to be remarkably effective in preventing the progression of established aneurysms. Rapamycin-induced aneurysm inhibition was accompanied by relative preservation in aortic architecture and reduced inflammation. These results lend further support to existing data supporting rapamycin as a prime translational candidate in early AAA disease suppression. 20, 21 Macrophages are likely the principal effector cells of aneurysmal disease, contributing to aortic degradation via the production of extracellular matrix-degrading proteinases, lipid mediators, reactive oxygen species, and proinflammatory cytokines.
23e25 Aortic hemodynamic conditions modulated aortic mural macrophage density and aneurysm progression, 26 as well as deficiency or inhibition of the chemokine receptor CCR2 or its ligand CCL2. More recently, the cyclic peptide MKEY, an inhibitor of CCL5eCXCL4 chemokine interaction, was also found to limit experimental aneurysm progression while reducing mural monocyte migration and macrophage density. 8 The effect of rapamycin treatment on mural inflammation and aneurysm initiation/progression has been previously investigated to varying degrees. Prior experiments have demonstrated the ability of rapamycin pretreatment to subsequently suppress aneurysm progression following subsequent AAA initiation, without apparently influencing inflammatory cell infiltration. 20 Discrepancy between those findings and the results of the current study may be owing to the fivefold higher rapamycin dose employed in the latter (although also administered by oral gavage).
Mural macrophage density is the summative end-organ consequence of several related cellular processes, including monocyte mobilization from systemic stores in the bone marrow and spleen, transendothelial migration from the bloodstream to inflamed aorta, and in situ macrophage proliferation, retention, egress, and cell death. 32, 33 In patients with chronic stable angina, the use of rapamycin-coated coronary stents was associated with reduced serum CCL2 levels. 34 Rapamycin down-regulated monocyte CCR2 and CCR5 expression, 35 and inhibited in vitro monocyte migration towards CCL2 and other chemoattractants. 36 Rapamycin also inhibited vascular endothelial growth factor (VEGF)-A production, another factor regulating influence on monocyte migration. 16, 37, 38 In congenitally hyperlipidemic mice, pretreatment with rapamycin was recently shown to reduce aneurysm formation after exogenous angiotensin (Ang) II infusion, in conjunction with a reduction in circulating monocytes, and monocyte CCR2 expression. 21 Thus, despite earlier findings to the contrary, rapamycin may limit experimental aneurysm initiation/progression through influences on monocyte mobilization, migration, or tissue differentiation.
In this study, rapamycin also reduced aortic mural neovascularization in experimental AAAs. Although we observed a trend that reduced aortic neovascularization correlated with the attenuation of aortic enlargement to a certain extent, it did not reach statistical significance (Spearman's rank correlation ¼ 0.6, p > .05, data not shown). While the significance of this finding may have been obscured by insufficient power, given the number of mice examined in this experiment, abundant prior observations link mural angiogenesis and AAA progression. 37,39e43 Angiogenesis is tightly regulated by the transcription factor, hypoxia inducible factor (HIF-1a). In addition to hypoxia, growth factors, inflammatory cytokines, and reactive oxygen species also modulate aortic cellular expression of HIF-1a (and VEGF-A) in AAA disease. 3,24,25,41,42,43e50 Because cellular levels vary, in part, owing to mTOR-mediated signaling pathways, 51 rapamycin may attenuate AAA progression through influences on HIF-1a-mediated aortic mural angiogenesis.
Several alternative immunosuppression reagents have been shown to prevent experimental AAA formation, and azathioprine and cyclosporine specifically prevent the progression of established AAAs. 4, 5, 52, 53 Interestingly, however, in patients receiving these drugs for long-term immunosuppression, existing AAA growth has been unaffected or even accelerated. 54, 55 Rapamycin may fare differently in this regard. For example, in addition to its influences on aortic mural macrophage density and neoangiogenesis, rapamycin inhibits T cell production of interferon-g and interleukin-17, important mediators of AAA progression, 23, 56 and induces regulatory T cells, a negative regulator for aneurysm disease. 57, 58 Rapamycin also diminishes classically activated macrophage polarization in experimental aneurysm models. 21 Finally, we and others have demonstrated the critical role of Ang II receptor in AAA pathogenesis, even in models created without exogenous Ang II administration. 22, 59 Among many other pro-aneurysmal influences on the aorta, Ang II also activates the mTOR pathway in vascular constitutive cells. 60, 61 Thus many properties of rapamycin, apart from its known influences on immunological competence, may account for its effectiveness in experimental (and potentially clinical) AAA suppression.
Because the primary goal of these experiments was to examine the influence of rapamycin on the progression of established AAAs, some limitations exist regarding the generalizeability of these results. As has been reported previously in the experimental literature, the dose of rapamycin employed (5 mg/kg/day) was far higher than the standard human clinical dose (up to 40 mg daily [<1 mg/ kg/day], and more typically 2e5 mg daily for maintenance dosing) (USPI guide for oral rapamune/sirolimus therapy; Pfizer, Philadelphia, PA, USA). The question of whether rapamycin, in the clinical dosing range, is effective at limiting experimental AAA progression was not specifically ManneWhitney test, **p < .01 compared with vehicle group; n ¼ 7e8 mice/group. addressed in this study. Similarly, a dose-ranging experiment was also outside the scope of this investigation. Given its long half-time (approximately 60 hours), a reduced frequency of administration may also maintain efficacy at lower total doses. Thus, substantial work will be required before clinical trials can be justified in patients with early AAA disease. Evaluation of the therapeutic efficacy of rapamycin was limited to transabdominal ultrasonography in vivo and aortic histological analyses. Further exploration of the cellular and molecular mechanisms responsible for the suppression of AAA progression by rapamycin are beyond the scope of this evaluation. Effects on aortic mural SMC preservation may be attributed to direct or indirect influences on apoptosis, survival, proliferation, and/or other regenerating properties of SMCs. Additionally, 10-day rapamycin treatment led to < 10.0% reduction body weight gain compared with vehicle treatment. Given the importance of body weight/mass on aneurysm growth, we cannot exclude the possibility that small reduced body weight gain by rapamycin may, in part, influence AAA growth.
CONCLUSION
Rapamycin limits progression of established experimental aneurysms, further supporting its translation potential in human AAA disease management.
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